D3250C00037 A multicenter, open-label, safety extension study with benralizumab (MEDI-563) for asthmatic adults on inhaled corticosteroid plus long-acting ss2 agonist (MELTEMI)

Administered By

Awarded By

Contributors

Start/End

  • July 1, 2016 - January 29, 2019